Related Experiment Video
Updated: May 26, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Drug interactions and long-term antidiabetic therapy
A W Logie1, D B Galloway, J C Petrie
1Department of Therapeutics and Clinical Pharmacology, University of Aberdeen, Foresterhill, Aberdeen AB9 2ZD.
British Journal of Clinical Pharmacology
|January 6, 2012
Summary
Drug interactions negatively impact diabetes control, especially for patients on sulphonylureas. Older patients taking barbiturates or diuretics experienced worse outcomes, highlighting the need for interaction prevention systems.
Area of Science:
- Clinical Pharmacy
- Pharmacology
- Endocrinology
Background:
- Drug interactions pose a significant risk in managing chronic conditions like diabetes.
- Polypharmacy is common among diabetic patients, increasing the likelihood of interactions with antidiabetic agents.
Purpose of the Study:
- To determine the prevalence of drug interactions involving antidiabetic medications.
- To evaluate the clinical significance of these interactions on diabetes control.
Main Methods:
- A study was conducted on 709 patients at the Aberdeen Diabetic Clinic.
- Patient medication data and diabetes control metrics from outpatient visits were analyzed.
Main Results:
- Over 50% of patients were exposed to drugs with potential interactions with their antidiabetic therapy.
- Diabetes control was significantly worse in sulphonylurea patients exposed to interacting drugs, particularly older individuals on barbiturates or diuretics.
- No adverse effect on control was observed in insulin or biguanide users.
Conclusions:
- Drug interactions, especially with sulphonylureas, can adversely affect glycemic control.
- A system to prevent drug interactions in patients on hypoglycaemic agents is proposed.
Related Concept Videos
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...